Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBUNASDAQ:CRVONASDAQ:LIANNASDAQ:MCRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBUCaribou Biosciences$0.80-5.8%$0.93$0.66▼$3.93$74.57M2.361.56 million shs771,832 shsCRVOCervoMed$10.56+16.6%$7.78$1.80▼$25.69$91.90M0.211.32 million shs1.21 million shsLIANLianBio$0.20+2.6%$0.20$0.27▼$4.99$21.61M0.231.04 million shs20,912 shsMCRBSeres Therapeutics$9.50-2.1%$12.45$7.18▼$30.60$82.82M2.54156,444 shs43,184 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBUCaribou Biosciences-0.16%+1.02%-6.81%-35.05%-76.56%CRVOCervoMed-3.41%+0.44%-0.98%+302.67%-62.70%LIANLianBio0.00%-4.95%+0.11%-4.95%-41.47%MCRBSeres Therapeutics+3.19%-0.31%-30.72%-43.37%-51.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRBUCaribou Biosciences2.4571 of 5 stars3.52.00.00.01.63.30.6CRVOCervoMed3.5944 of 5 stars4.44.00.00.02.81.70.6LIANLianBioN/AN/AN/AN/AN/AN/AN/AN/AMCRBSeres Therapeutics3.3357 of 5 stars3.02.00.04.61.91.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBUCaribou Biosciences 3.00Buy$9.331,064.05% UpsideCRVOCervoMed 2.89Moderate Buy$27.50160.42% UpsideLIANLianBio 0.00N/AN/AN/AMCRBSeres Therapeutics 2.00Hold$80.00742.11% UpsideCurrent Analyst Ratings BreakdownLatest LIAN, MCRB, CRVO, and CRBU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025CRBUCaribou BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $3.003/26/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/20/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/19/2025CRBUCaribou BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/18/2025CRVOCervoMedRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $20.003/18/2025CRVOCervoMedCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $21.003/17/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/14/2025MCRBSeres TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $15.003/13/2025CRVOCervoMedJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.003/13/2025CRVOCervoMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00 ➝ $14.003/11/2025CRVOCervoMedBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBUCaribou Biosciences$9.99M7.46N/AN/A$4.17 per share0.19CRVOCervoMed$7.14M12.87N/AN/A$1.30 per share8.12LIANLianBioN/AN/AN/AN/A$2.71 per shareN/AMCRBSeres Therapeutics$126.33M0.66N/AN/A($0.35) per share-27.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBUCaribou Biosciences-$102.07M-$1.65N/AN/AN/A-1,290.81%-45.46%-38.07%5/6/2025 (Estimated)CRVOCervoMed-$2.17M-$2.03N/AN/AN/A-118.68%-44.11%-39.81%5/13/2025 (Estimated)LIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/AMCRBSeres Therapeutics-$113.72M-$4.60N/AN/AN/AN/AN/A-55.08%5/7/2025 (Estimated)Latest LIAN, MCRB, CRVO, and CRBU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CRVOCervoMed-$0.60N/AN/AN/A$1.70 millionN/A5/7/2025Q1 2025MCRBSeres Therapeutics-$0.03N/AN/AN/A$10.00 millionN/A5/6/2025Q1 2025CRBUCaribou Biosciences-$0.42N/AN/AN/AN/AN/A3/17/2025Q4 2024CRVOCervoMed-$0.67-$0.80-$0.13-$0.80$1.51 million$2.16 million3/10/2025Q4 2024CRBUCaribou Biosciences-$0.40-$0.39+$0.01-$0.39$2.11 million$2.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBUCaribou BiosciencesN/AN/AN/AN/AN/ACRVOCervoMedN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBUCaribou BiosciencesN/A7.387.38CRVOCervoMedN/A15.0415.04LIANLianBioN/A10.0610.06MCRBSeres TherapeuticsN/A1.121.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBUCaribou Biosciences77.51%CRVOCervoMed25.15%LIANLianBio74.85%MCRBSeres Therapeutics59.34%Insider OwnershipCompanyInsider OwnershipCRBUCaribou Biosciences9.50%CRVOCervoMed36.30%LIANLianBio7.59%MCRBSeres Therapeutics4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBUCaribou Biosciences10093.01 million81.95 millionOptionableCRVOCervoMed48.70 million3.93 millionNot OptionableLIANLianBio110108.06 million99.86 millionNot OptionableMCRBSeres Therapeutics3308.72 million162.03 millionOptionableLIAN, MCRB, CRVO, and CRBU HeadlinesRecent News About These CompaniesSeres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune DiseasesApril 29 at 7:00 AM | globenewswire.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Sees Large Decrease in Short InterestApril 28 at 5:38 PM | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Hits New 12-Month Low - Here's What HappenedApril 25, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Shares Up 10% - Still a Buy?April 24, 2025 | marketbeat.comPetri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock splitApril 24, 2025 | bizjournals.comSeres Therapeutics trading resumesApril 24, 2025 | markets.businessinsider.comSeres Therapeutics trading halted, volatility trading pauseApril 24, 2025 | markets.businessinsider.comSeres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025April 23, 2025 | globenewswire.comSeres Therapeutics trading halted, news pendingApril 22, 2025 | markets.businessinsider.comWhy Seres Therapeutics, Inc.’s (MCRB) Stock Is Up 10.81%April 21, 2025 | aaii.comDown -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a TurnaroundApril 17, 2025 | zacks.comWhy Seres Therapeutics, Inc.’s (MCRB) Stock Is Up 7.28%April 14, 2025 | aaii.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Receives Consensus Rating of "Hold" from BrokeragesApril 9, 2025 | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | msn.comSeres Therapeutics (MCRB) Gets a Hold from Piper SandlerMarch 14, 2025 | markets.businessinsider.comSeres Therapeutics reports FY24 EPS (81c), consensus (20c)March 13, 2025 | markets.businessinsider.comSeres Therapeutics, Inc.: Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 13, 2025 | finanznachrichten.deSeres Therapeutics announces anticipated upcoming milestonesMarch 13, 2025 | markets.businessinsider.comSeres Therapeutics sees cash runway into 1Q26March 13, 2025 | markets.businessinsider.comSeres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | seekingalpha.comSeres Therapeutics, Inc. 2024 Q4 - Results - Earnings Call PresentationMarch 13, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonIntel-Taiwan Semiconductor Alliance Fuels Turnaround HopesBy Jeffrey Neal Johnson | April 8, 2025View Intel-Taiwan Semiconductor Alliance Fuels Turnaround HopesMeta Eyes India: Breaking Down Its Quest for Reliance PartnershipBy Leo Miller | April 7, 2025View Meta Eyes India: Breaking Down Its Quest for Reliance PartnershipLIAN, MCRB, CRVO, and CRBU Company DescriptionsCaribou Biosciences NASDAQ:CRBU$0.80 -0.05 (-5.77%) Closing price 04:00 PM EasternExtended Trading$0.80 0.00 (-0.22%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.CervoMed NASDAQ:CRVO$10.56 +1.50 (+16.56%) Closing price 04:00 PM EasternExtended Trading$11.86 +1.30 (+12.26%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.LianBio NASDAQ:LIAN$0.20 +0.01 (+2.56%) As of 04/30/2025LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.Seres Therapeutics NASDAQ:MCRB$9.50 -0.20 (-2.06%) Closing price 04:00 PM EasternExtended Trading$9.49 -0.01 (-0.05%) As of 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
